We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 954

Divisional Court allows examinations by non-health practitioners: Ziebenhaus v. Bahlieda, 2014 ONSC 138

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • June 27 2014

The Divisional Court recently held that a Superior Court Judge has inherent jurisdiction to order a party to be examined by a non-health practitioner

Federal Court grants injunction that allows infringing biologic drug to stay on the market

  • Norton Rose Fulbright Canada LLP
  • -
  • Canada
  • -
  • June 20 2014

Case: AbbVie Corporation, AbbVie Deutschland GMBH & Co. KG and AbbVie Biotechnology Ltd. v. Janssen Inc., 2014 FC 489 Drug: Ustekinumab (STELARA®

Personalized medicine: patent issues in Canada and Europe

  • Gowling Lafleur Henderson LLP
  • -
  • Canada, European Union
  • -
  • June 19 2014

"Personalized medicine," in its broadest aspects, is essentially the tailoring of treatments to individual characteristics, needs and preferences

Plaintiff’s right to videorecord independent medical examinations andor to have a nominee present

  • Field Law
  • -
  • Canada
  • -
  • February 21 2013

The plaintiff sued for personal injury as a result of a motor vehicle accident that occurred on 14 November, 2007. The plaintiff alleged injuries to

BBM Canada v. Research in Motion Limited

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • May 16 2011

This was an appeal from a decision that found a claim relating to trade-mark infringement, depreciation of goodwill and passing off may not be brought as an application in the Federal Court

USPTO issues new subject matter guidance post-Myriad and Prometheus

  • Bereskin & Parr LLP
  • -
  • Canada
  • -
  • March 7 2014

The United States Patent and Trademark Office (USPTO) issued a new guidance document for Examiners on March 4, 2014, effective immediately

Permanent injunction granted despite patentee not having a product that practiced the claims of the patent

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • June 18 2014

On May 22, 2014, the Federal Court of Canada issued an injunction curtailing Janssen Inc.’s marketing of its drug ustekinumab (STELARA) in ongoing

Final injunction permits existing patients to continue to receive infringing medicine

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • June 10 2014

This decision relates to the crafting of a final injunction for the sale of STELARA following a finding of infringement. In an earlier trial decision

New guideposts for the fact-intensive hypothetical world of generic damages claims

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • June 14 2014

The past year has seen significant evolution in the Canadian law of generic pharmaceutical damages claims under section 8 of the Patented Medicines

Federal court dismisses notion that patents should be given only one interpretation for all purposes

  • McCarthy Tétrault LLP
  • -
  • Canada
  • -
  • June 19 2014

In a pair of simultaneously released decisions on June 13, 2014, Justice O'Reilly allowed Allergan's applications (the "Applications") prohibiting